After >5 yr of follow-up, enzalutamide continued to demonstrate improved long-term survival despite placebo crossover and multiple subsequent effective therapies in asymptomatic or mildly symptomatic men with metastatic castration-resistant prostate cancer. We identify clinical risk groups with widely disparate long-term survival.
- Metastatic castration-resistant prostate cancer
- Multivariable model
- Overall survival
- Prostate-specific antigen
ASJC Scopus subject areas